S&P raises ResMed ratings
Monday, 01 September, 2003
Standard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'.
The upgrade reflects ResMed's extended favourable operating performance and Standard & Poor's "increased confidence in the company's ability to build its market presence", S&P said in a statement.
"The speculative-grade ratings on ResMed reflect the niche medical equipment supplier's fast growth as it capitalises on the emerging market for sleep apnoea treatment," said Standard & Poor's credit analyst Jordan Grant. "This growth is offset by the company's still-limited size and resources."
The mostly untapped obstructive sleep apnoea and sleep-disordered breathing markets offer significant growth opportunities for ResMed, according to S&P. As the company has capitalised on this market potential, its revenue has grown by more than 30 per cent in each of the past two years.
The company faces competition in its principal geographic markets from larger competitors such as Respironics and Nellcor Puritan Bennett (a division of Tyco), both of which have greater financial capabilities than ResMed.
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
